07:00 , May 5, 2016 |  BC Innovations  |  Targets & Mechanisms

Better call Delilah

Long non-coding RNAs (lncRNAs), once confined to the pile of non-functional genomic "junk," are now recognized to play key roles in gene regulation, and are increasingly being explored in various cancers. A Belgian group has...
08:00 , Jan 11, 2016 |  BC Week In Review  |  Clinical News

Emricasan: Phase II data

A double-blind, U.S. Phase II trial in 86 patients with liver cirrhosis showed that twice-daily 25 mg oral emricasan significantly reduced cleaved CK18 levels from baseline to 3 months vs. placebo (reduction of 4.6% vs....
07:00 , May 4, 2015 |  BC Week In Review  |  Clinical News

Emricasan: Additional Phase II data

Additional data from a double-blind, U.S. Phase II trial in 38 patients with NAFLD, including patients with non-alcoholic steatohepatitis (NASH), showed that twice-daily 25 mg emricasan led to a median absolute reduction in ALT levels...
07:00 , Mar 30, 2015 |  BC Week In Review  |  Clinical News

Emricasan: Phase II data

Top-line data from a double-blind, U.S. Phase II trial in 38 patients with NAFLD, including patients with non-alcoholic steatohepatitis (NASH), showed that twice-daily 25 mg emricasan met the primary endpoint of reducing ALT levels from...
08:00 , Feb 16, 2015 |  BC Week In Review  |  Clinical News

Emricasan: Phase I data

An open-label, U.S. Phase I trial showed that a single dose of 50 mg oral emricasan led to no notable reductions in caspase-mediated biomarkers in patients with severe hepatic impairment or in healthy matched controls....
08:00 , Feb 16, 2015 |  BC Week In Review  |  Clinical News

Emricasan: Phase II data

Top-line data from a double-blind, placebo-controlled, U.S. and U.K. Phase II trial in 21 patients with ACLF showed that twice-daily 25 and 50 mg oral emricasan for 28 days reduced cleaved cytokeratin 18 ( CK18;...
07:00 , Mar 10, 2014 |  BC Week In Review  |  Clinical News

Emricasan: Phase II started

Conatus began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate 25 mg oral emricasan twice daily for 28 days in about 40 patients with non-alcoholic fatty liver disease, including those with inflammatory and/or fibrotic...
07:00 , Sep 12, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Caspase-3 (CASP3; CPP32) In vitro studies identified specific CASP3 inhibitors that...
07:00 , Jun 10, 2013 |  BioCentury  |  Emerging Company Profile

ONL Therapeutics: Eyeing Fas

ONL Therapeutics LLC is developing a peptide antagonist of Fas-mediated apoptosis that could become the first pharmacotherapy to prevent vision loss associated with non-exudative retinal detachment. The company expects its products would be used as...
07:00 , Mar 24, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD); Parkinson's disease (PD) Caspase-3 (CASP3; CPP32); CASP7 (MCH3); CASP8 (FLICE)...